Detalles de la búsqueda
1.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Support Care Cancer
; 30(3): 2455-2465, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779921
2.
Response to cabozantinib in renal cell carcinoma with cardiac metastases.
Anticancer Drugs
; 31(3): 314-318, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31929349
3.
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference.
Int J Colorectal Dis
; 35(8): 1513-1527, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32382835
4.
Facing SARS-CoV-2 outbreak in immunotherapy era.
Future Oncol
; 16(20): 1475-1485, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32468851
5.
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.
Br J Cancer
; 121(7): 593-599, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31474758
6.
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Target Oncol
; 19(3): 371-382, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38613732
7.
The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients.
J Cell Mol Med
; 17(11): 1415-21, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24283947
8.
New molecular insights in tobacco-induced lung cancer.
Future Oncol
; 9(5): 649-55, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23647294
9.
Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
Future Oncol
; 9(12): 1809-11, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24295410
10.
Acute left-sided malignant colonic obstruction: Is there a role for endoscopic stenting?
World J Clin Oncol
; 14(5): 190-197, 2023 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37275939
11.
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Front Oncol
; 13: 1125013, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36895480
12.
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis.
Cancers (Basel)
; 15(11)2023 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37297026
13.
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Curr Oncol
; 30(6): 5456-5469, 2023 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37366896
14.
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
Cancers (Basel)
; 15(24)2023 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38136304
15.
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
J Geriatr Oncol
; 13(3): 302-307, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716122
16.
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.
Clin Colorectal Cancer
; 21(3): 220-228, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35304089
17.
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Eur J Cancer
; 170: 64-72, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35594613
18.
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis.
Front Oncol
; 12: 935826, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36033477
19.
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Clin Colorectal Cancer
; 20(4): 318-325, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34380594
20.
Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis.
Eur J Cancer
; 146: 145-154, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33607478